News & Updates

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

A recent study suggests greater focus must be given on depression or anxiety symptoms than an actual diagnosis of these psychological disorders in predicting who among people with inflammatory bowel disease (IBD) will have a need for mental health care.